Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TumorGlow™ - CNS: ICG for Intraoperative Imaging of CNS Tumors
NCT05746104Phase 1Enrolling by invitation
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in central nervous system tumor, sponsored by Abramson Cancer Center. Primary endpoints: Tumor NIR Signal Compared to Background Brain Normal Signal at Day 0, Near-Infrared Efficiency at Day 0 and 1 more. Started Mar 2023; status: enrolling by invitation.
02
Drugs
indocyanine green
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT05746104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746104.